相似文献
1
Multiple Sclerosis.
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
2
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Pract Neurol. 2016 Feb;16(1):4-6. doi: 10.1136/practneurol-2015-001209. Epub 2015 Oct 1.
3
Multiple sclerosis disease-modifying therapy and pregnancy.
Mult Scler. 2016 May;22(6):715-6. doi: 10.1177/1352458516642316.
4
Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
J Manag Care Pharm. 2007 Apr;13(3):287-9. doi: 10.18553/jmcp.2007.13.3.287.
5
Multiple sclerosis: monotherapy rules.
Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886.
6
[Magnetic resonance angiography in multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(12):53-7.
7
Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.
Curr Opin Neurol. 2001 Jun;14(3):259-69. doi: 10.1097/00019052-200106000-00002.
8
Interferon beta and glatiramer acetate therapy.
Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4.
9
[Biological treatment of multiple sclerosis].
Ugeskr Laeger. 2008 Jun 9;170(24):2156-9.
10
Pharmacologic management of multiple sclerosis.
Urol Nurs. 2008 Jun;28(3):217-9.
引用本文的文献
1
Circadian Clock: A Regulator of Immunity in Autoimmune Diseases.
Immun Inflamm Dis. 2025 Sep;13(9):e70246. doi: 10.1002/iid3.70246.
2
Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.
BMC Med. 2025 Sep 2;23(1):514. doi: 10.1186/s12916-025-04366-7.
3
Influence of OSCAR-IB Criteria on Test-Retest Reliability of Cirrus HD-OCT Retinal Thickness Measurements in People With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm. 2025 Nov;12(6):e200458. doi: 10.1212/NXI.0000000000200458. Epub 2025 Aug 29.
4
Flecainide mediated sodium channel blockade enhances blood brain barrier integrity and promotes neuroprotection in neuroinflammation.
Sci Rep. 2025 Aug 23;15(1):31032. doi: 10.1038/s41598-025-15430-w.
5
Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS.
Front Immunol. 2025 Aug 1;16:1604987. doi: 10.3389/fimmu.2025.1604987. eCollection 2025.
6
BrainAgeNeXt: Advancing brain age modeling for individuals with multiple sclerosis.
Imaging Neurosci (Camb). 2025 Feb 25;3. doi: 10.1162/imag_a_00487. eCollection 2025.
7
Microstructure-informed brain tissue classification using clustering of quantitative MRI measures.
Imaging Neurosci (Camb). 2025 Apr 3;3. doi: 10.1162/imag_a_00526. eCollection 2025.
8
Investigation of BTK as a Potent Immunomodulatory Target: Exploring Novel Therapeutic Approaches for Multiple Sclerosis.
ACS Omega. 2025 Jul 22;10(30):33481-33496. doi: 10.1021/acsomega.5c03682. eCollection 2025 Aug 5.
9
Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis.
J Neuroinflammation. 2025 Aug 7;22(1):200. doi: 10.1186/s12974-025-03519-y.
10
Response to therapy in a cohort of patients with late-onset multiple sclerosis.
Mult Scler J Exp Transl Clin. 2025 Jul 29;11(3):20552173251360357. doi: 10.1177/20552173251360357. eCollection 2025 Jul-Sep.
本文引用的文献
1
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet Neurol. 2017 Nov;16(11):877-897. doi: 10.1016/S1474-4422(17)30299-5. Epub 2017 Sep 17.
2
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.
Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12.
3
Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.
4
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11.
5
Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.
J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z.
6
T-bet-dependent NKp46 innate lymphoid cells regulate the onset of T17-induced neuroinflammation.
Nat Immunol. 2017 Oct;18(10):1117-1127. doi: 10.1038/ni.3816. Epub 2017 Aug 14.
7
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.
Nat Rev Neurol. 2017 Jul;13(7):391-405. doi: 10.1038/nrneurol.2017.81. Epub 2017 Jun 16.
8
NG2 plays a role in neuroinflammation but is not expressed by immune cells.
Acta Neuropathol. 2017 Aug;134(2):325-327. doi: 10.1007/s00401-017-1735-5. Epub 2017 May 31.
9
Defining Disease Activity and Response to Therapy in MS.
Curr Treat Options Neurol. 2017 May;19(5):20. doi: 10.1007/s11940-017-0454-5.
10
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
Drugs. 2017 May;77(8):885-910. doi: 10.1007/s40265-017-0726-0.
Zotero 插件